

Session 3: An Update on Critical Issues for Alzheimer's Disease

ISCTM Chair:
Ravi Anand

ECNP Chair:
Gitte Knudsen



Session 3-I Speakers

- Ravi Anand: Progress in the treatment of Alzheimer's Disease: are we at a crossroad?
- John Hardy: Amyloid pathways and disease-modifying treatments for AD: what changes are necessary in new trials?
- Philip Scheltens: Do findings from observational studies explain failure of disease-modifying trials: implications for future trials?

Session 3-II Speakers

- Rachelle Doody: Evidence from amyloid-modifying treatments: Are we learning anything about the treatment of AD?
- Bruno Dubois: Critical Issues for Alzheimer's Disease
- George Grossberg: Is there a need for new symptomatic therapies for Alzheimer's Disease and what have we learned from the past trials of symptomatic therapies?
- Karl Broich: Regulatory efforts to streamline the pathway for developing novel treatments for AD

Overview

- Criteria for AD diagnosis (Dubois)
- Amyloid hypothesis (Anand)
- Amyloid trials (Hardy & Doody)
- Symptomatic treatment (Grossberg)
- Future clinical trials (Scheltens)
- Regulatory efforts (Broick)

